NeuroOne Medical Technologies Corporation NMTC
0.95 USD -0.03 (-3.06%)
At closeNov 4, 2026, 4:00 PM EST
0.93 -0.02 -2.11%
After hours · Nov 4, 4:00 PM ET
0.944 Day range 1.01
0.772 52-week range 6.12
- YTD
- -79.12%
- 1 year
- -78.11%
- Market cap
- 8.65M
- Revenue (ttm)
- 3.92M
- EPS (ttm)
- -0.99
- Shares out
- 30.84M
- Forward P/E
- -2.65
- YTD return
- -79.12%
- 1-year return
- -78.11%
- Volume
- 92.81K
- Avg volume
- 344.78K
- Open
- 0.98
- Previous close
- 0.98
- Day's range
- 0.944 – 1.01
- 52-week range
- 0.772 – 6.12
- Beta
- 0.91
5D +0.1272 (+15.75%)
Key statistics
- Enterprise value
- 23.04M
- PEG ratio
- 0.00
- Price / sales
- 5.83
- Price / book
- 6.87
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 31.10%
- Free cash flow
- -6.99M
- Total cash
- 1.62M
- Total debt
- 290.09K
- Return on equity
- -349.13%
- Short % of float
- 0.32%
- 50-day average
- 0.81312
- 200-day average
- 0.92463
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
NMTC Revenue — quarterly 1.97M
NMTC Net income — quarterly -2.01M
NMTC EPS — quarterly -0.23
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 17, 2024 | Sep 1, 2024 | 0.00 | -0.11 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.10 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -0.11 | — | — |
| Feb 13, 2024 | Dec 1, 2023 | 0.00 | -0.14 | — | — |
| Dec 14, 2023 | Sep 1, 2023 | 0.00 | -0.13 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.20 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2023 | Alliance Global Partners | main | Buy | Buy |
| Mar 28, 2022 | Craig-Hallum | down | Buy | Hold |
| Dec 3, 2021 | Alliance Global Partners | init | — | Buy |
| Nov 15, 2021 | Craig-Hallum | init | — | Buy |
About NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- n1mtc.com
News
NeuroOne Medical Technologies Publishes Initial Clinical Results For Its OneRF Trigeminal Nerve Ablation System 
NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System 
NeuroOne Featured in New York Post on OneRF® Patient's Remarkable Journey to Overcome Debilitating Facial Pain 
12 Health Care Stocks Moving In Thursday's After-Market Session 
NeuroOne Secures First Pharmaceutical Industry Purchase Order For StereoCED Drug Delivery Platform; No Terms Disclosed 
NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program 
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Stock Short Interest Climbs 135.8% 
12 Health Care Stocks Moving In Thursday's After-Market Session 
NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology 
NeuroOne (NASDAQ: NMTC) secures a $4.5M order as revenue climbs again
Your note
Sign in to keep a note on NMTC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDRLE EDWARD | Director | Stock Award(Grant) | Jun 1, 2020 | 29,435 |
| BACHINSKI THOMAS | Officer | Stock Award(Grant) | Jul 19, 2017 | 215,453 |
| BUCKMAN PAUL R | Director | Stock Award(Grant) | Jun 1, 2020 | 80,495 |
| CHRISTIANSON MARK | Officer | Sale | Jun 11, 2020 | 1,089,210 |
| FREDRICKSON WADE | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 28, 2018 | 2,613,460 |
| KALIA SURAJ CFA | Director | Stock Award(Grant) | Jun 3, 2019 | 14,006 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AWM Investment Company, Inc. | 10.03% | 1,200,000 | 890.40K | Sep 29, 2024 |
| Vanguard Group Inc | 7.69% | 919,528 | 682.29K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 6.68% | 798,762 | 592.68K | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.37% | 283,855 | 210.62K | Sep 29, 2024 |
| Perkins Capital Management, Inc. | 1.25% | 150,000 | 111.30K | Sep 29, 2024 |
| State Street Corporation | 0.50% | 59,499 | 44.15K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5.96% | 712,451 | 528.64K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.73% | 207,077 | 153.65K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 1.34% | 160,800 | 119.31K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.33% | 39,988 | 29.67K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.32% | 37,969 | 28.17K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.13% | 15,540 | 11.53K | Oct 30, 2024 |